Regulatory21 Sep 2026 · 8:26 AM IST
BIOCONBiocon
Pertuzumab biosimilar gets a positive opinion from Europe's CHMP
It is the first biosimilar recommended under a new tailored clinical approach.
Price, Friday's close₹385.00▲ 1.32%
Last 5 days
What happened
- Biocon's Pertuzumab received an approval recommendation from the European Medicines Agency's CHMP, the first biosimilar under a new tailored clinical approach.
Read the source
This is a summary of public news about Biocon, for information only. It is not a recommendation to buy, sell or hold BIOCON.
Biocon in the news before
- 8 SEP 2026 · ORDERSWins a 10-year supply contract for Pertuzumab in Brazil